1. Home
  2. URG vs KMDA Comparison

URG vs KMDA Comparison

Compare URG & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ur Energy Inc (Canada)

URG

Ur Energy Inc (Canada)

HOLD

Current Price

$1.25

Market Cap

477.8M

ML Signal

HOLD

Logo Kamada Ltd.

KMDA

Kamada Ltd.

HOLD

Current Price

$7.02

Market Cap

385.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
URG
KMDA
Founded
2004
1990
Country
United States
Israel
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
477.8M
385.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
URG
KMDA
Price
$1.25
$7.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$2.52
$13.00
AVG Volume (30 Days)
9.9M
102.2K
Earning Date
11-03-2025
11-10-2025
Dividend Yield
N/A
2.85%
EPS Growth
N/A
30.41
EPS
N/A
0.35
Revenue
$39,411,000.00
$174,787,000.00
Revenue This Year
N/A
$14.90
Revenue Next Year
$183.54
$9.91
P/E Ratio
N/A
$19.76
Revenue Growth
138.94
10.36
52 Week Low
$0.55
$5.54
52 Week High
$2.35
$9.16

Technical Indicators

Market Signals
Indicator
URG
KMDA
Relative Strength Index (RSI) 41.24 55.02
Support Level $1.17 $6.63
Resistance Level $1.46 $7.07
Average True Range (ATR) 0.07 0.13
MACD 0.01 0.02
Stochastic Oscillator 27.62 70.32

Price Performance

Historical Comparison
URG
KMDA

About URG Ur Energy Inc (Canada)

Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Share on Social Networks: